New knowledge of the mechanisms of sorafenib resistance in liver cancer
Acta Pharmacologica Sinica2017Vol. 38(5), pp. 614–622
Citations Over TimeTop 1% of 2017 papers
Related Papers
- → Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma(2021)11 cited
- → Selection of Patients with Hepatocellular Carcinoma for Sorafenib(2009)36 cited
- The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells.(2019)
- Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.(2014)
- → Μελέτη της επιδράσεως του αντιαγγειογενετικού παράγοντα sorafenib στην ηπατική αναγέννηση(2015)